Christoph Bergmann
Research Subjects
Christoph Bergmann has a total of 212 co-authors. Here are the top co-authors by number of shared publications:
- Erika Jensen-Jarolim
Institute of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology Medical University of Vienna Vienna Austria
9 shared publications - Aurélie Poli
Neuro‐Immunology Group, Department of Cancer Research Luxembourg Institute of Health Luxembourg Luxembourg
8 shared publications - Heather J. Bax
King’s College London
8 shared publications - Leticia de Las Vecillas
Department of Allergy La Paz University Hospital Madrid Spain
8 shared publications - Sophia N. Karagiannis
King’s College London
8 shared publications - Elena Izquierdo
Universidad CEU San Pablo Facultad de Medicina
7 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 9 February 2026
- Published by Springer Nature in Current Treatment Options in Allergy
- Vol. 13 (1)
Broad-Spectrum Grass Pollen Immunotherapy: Revisiting the Role of Species Diversity in Allergy Treatment
Purpose of Review: This review examines whether allergen immunotherapy (AIT) for grass pollen allergy should expand beyond the recent trend towards a mono-species approach based on Phleum pratense . It explores whether multi-species formulations better reflect natural exposure and could improve clinical outcomes. Recent Findings: Research from aerobiology and immunology shows that grass pollen exposure involves diverse species with distinct flowering periods, influenced by climate and geography. Molecular analyses reveal species-specific allergen profiles, including unique peptides and variations in major allergens such as Group 1 and 5. Patient data confirm symptom variability across the season. In-vitro studies have observed limits to the cross-reactivity of T-cell epitopes, and comparative clinical studies suggest benefits for multi-species treatment options. Summary: Evidence indicates that mono-species extracts alone do not represent the full allergenic spectrum of grass pollen. Broad-spectrum AIT formulations incorporating multiple grass species provide a more comprehensive repertoire of allergens and epitopes, potentially enhancing immunogenicity and therapeutic benefit. This supports the hypothesis that diversity does not equate to dilution in broad-spectrum formulations. The approach aligns with patient symptom patterns and may improve efficacy and asthma prevention. Future research could further refine species selection and leverage molecular diversity to optimize treatment strategies.
- 9 February 2026
- Published by Springer Nature in Current Treatment Options in Allergy
- Vol. 13 (1)
Top Cited PapersOpen AccessBroad-Spectrum Grass Pollen Immunotherapy: Revisiting the Role of Species Diversity in Allergy Treatment
Purpose of Review: This review examines whether allergen immunotherapy (AIT) for grass pollen allergy should expand beyond the recent trend towards a mono-species approach based on Phleum pratense . It explores whether multi-species formulations better reflect natural exposure and could improve clinical outcomes. Recent Findings: Research from aerobiology and immunology shows that grass pollen exposure involves diverse species with distinct flowering periods, influenced by climate and geography. Molecular analyses reveal species-specific allergen profiles, including unique peptides and variations in major allergens such as Group 1 and 5. Patient data confirm symptom variability across the season. In-vitro studies have observed limits to the cross-reactivity of T-cell epitopes, and comparative clinical studies suggest benefits for multi-species treatment options. Summary: Evidence indicates that mono-species extracts alone do not represent the full allergenic spectrum of grass pollen. Broad-spectrum AIT formulations incorporating multiple grass species provide a more comprehensive repertoire of allergens and epitopes, potentially enhancing immunogenicity and therapeutic benefit. This supports the hypothesis that diversity does not equate to dilution in broad-spectrum formulations. The approach aligns with patient symptom patterns and may improve efficacy and asthma prevention. Future research could further refine species selection and leverage molecular diversity to optimize treatment strategies.
- Open Access
Molecular Signatures and Functional Pathways of Human Monocytes and Macrophages in Allergy: An EAACI AllergoOncology Scoping Review
AllergoOncology explores the intersection of allergic diseases and cancer, focusing on shared immune mechanisms. While monocytes and macrophages are extensively studied in cancer, their roles in allergic diseases remain underexplored. To address this gap, we conducted a scoping review to systematically characterize the molecular landscape and related pathways of human monocytes and macrophages in allergy. An automated search of PubMed and Web of Science databases retrieved 4668 unique articles, which were manually curated based on predefined inclusion and exclusion criteria, yielding 138 eligible studies. From these, we identified 451 molecules associated with monocyte and macrophage responses across allergic disorders. Data analyses revealed a research bias towards blood‐derived monocytes, underrepresentation of tissue‐resident macrophages, and limited inclusion of miRNAs. Semantic similarity and pathway enrichment analyses highlighted a common molecular signature across major allergic disorders, with consistent enrichment in interleukin signaling and immune activation pathways. To enhance reproducibility and translational utility for researchers and clinicians, we developed ALO•HA , a web application for interactive data exploration. This overview of monocyte and macrophage molecular responses in human allergy underscores the need for integrative, human‐focused approaches to better define their roles, and to guide future therapeutic strategies in allergic diseases and at the interface with oncology.
Open AccessMolecular Signatures and Functional Pathways of Human Monocytes and Macrophages in Allergy: An EAACI AllergoOncology Scoping Review
AllergoOncology explores the intersection of allergic diseases and cancer, focusing on shared immune mechanisms. While monocytes and macrophages are extensively studied in cancer, their roles in allergic diseases remain underexplored. To address this gap, we conducted a scoping review to systematically characterize the molecular landscape and related pathways of human monocytes and macrophages in allergy. An automated search of PubMed and Web of Science databases retrieved 4668 unique articles, which were manually curated based on predefined inclusion and exclusion criteria, yielding 138 eligible studies. From these, we identified 451 molecules associated with monocyte and macrophage responses across allergic disorders. Data analyses revealed a research bias towards blood‐derived monocytes, underrepresentation of tissue‐resident macrophages, and limited inclusion of miRNAs. Semantic similarity and pathway enrichment analyses highlighted a common molecular signature across major allergic disorders, with consistent enrichment in interleukin signaling and immune activation pathways. To enhance reproducibility and translational utility for researchers and clinicians, we developed ALO•HA , a web application for interactive data exploration. This overview of monocyte and macrophage molecular responses in human allergy underscores the need for integrative, human‐focused approaches to better define their roles, and to guide future therapeutic strategies in allergic diseases and at the interface with oncology.
- Open Access
Basophil Activation Test: Bridging Allergy and Oncology for Diagnostic, Therapeutic and Prognostic Applications in AllergoOncology : An EAACI Position Paper
The basophil activation test (BAT) is gaining increasing relevance as an ex vivo functional assay in allergy to evaluate IgE‐mediated hypersensitivity reactions to food allergens, venoms, and drugs and to monitor tolerance induction. Establishing universal standard operating protocols has been difficult, due to several challenges including variable activation markers, positive control selection, the need for processing fresh blood samples, and the existence of non‐releasing individuals. In oncology, BAT is also an emerging promising diagnostic and management tool to assess hypersensitivity reactions to biologics and chemotherapy agents, monitor drug tolerance in desensitisation, and predict and address the safety of novel anti‐cancer IgE‐based therapeutics. This position paper highlights the emerging significance of BAT in AllergoOncology, in facilitating therapy monitoring, biomarker discovery, and risk stratification. Capitalising on long‐acquired expertise in the development of BAT for allergy, we propose research directions and routes to clinical applications of this highly promising tool in AllergoOncology. We advocate the need for enhanced focus on addressing standardisation challenges and leveraging outputs for precision medicine. By linking allergy and oncology, the key remaining limitations can be addressed, with the aim of realising the significant promise of BAT as a robust tool to enhance personalised care in allergy and AllergoOncology.
Open AccessBasophil Activation Test: Bridging Allergy and Oncology for Diagnostic, Therapeutic and Prognostic Applications in AllergoOncology : An EAACI Position Paper
The basophil activation test (BAT) is gaining increasing relevance as an ex vivo functional assay in allergy to evaluate IgE‐mediated hypersensitivity reactions to food allergens, venoms, and drugs and to monitor tolerance induction. Establishing universal standard operating protocols has been difficult, due to several challenges including variable activation markers, positive control selection, the need for processing fresh blood samples, and the existence of non‐releasing individuals. In oncology, BAT is also an emerging promising diagnostic and management tool to assess hypersensitivity reactions to biologics and chemotherapy agents, monitor drug tolerance in desensitisation, and predict and address the safety of novel anti‐cancer IgE‐based therapeutics. This position paper highlights the emerging significance of BAT in AllergoOncology, in facilitating therapy monitoring, biomarker discovery, and risk stratification. Capitalising on long‐acquired expertise in the development of BAT for allergy, we propose research directions and routes to clinical applications of this highly promising tool in AllergoOncology. We advocate the need for enhanced focus on addressing standardisation challenges and leveraging outputs for precision medicine. By linking allergy and oncology, the key remaining limitations can be addressed, with the aim of realising the significant promise of BAT as a robust tool to enhance personalised care in allergy and AllergoOncology.
Otitis Media With Effusion (OME) and Eustachian Tube Dysfunction: The Role of Allergy and Immunity—An EAACI Position Paper
IgE‐mediated allergies play a significant role in respiratory diseases. Given the similar mucosal epithelium of the upper and lower respiratory tracts and their shared (patho)physiological immune responses, the “unified airways” concept views these tracts as a single system. Recently, this model has been extended to include the middle ear, with studies confirming that the Eustachian tube and middle ear are both anatomically and functionally part of the upper airways. However, the relationship between allergies and middle ear disorders remains controversial, with conflicting findings regarding pathogenesis and treatment. The increasing prevalence of allergies highlights the importance of further research. In Germany, the current sensitization rate to aeroallergens is 33.6%, with similar trends across Europe, where rates commonly range up to 30%. This widespread increase underscores the urgent need for a deeper understanding of the correlation between allergies and middle ear disorders across diverse European populations. Ineffective pharmacotherapy or possibly harmful medication for acute and chronic OME, such as systemic steroids, is most likely used globally in an uninformed way, due to a lack of evidence on the connection between allergic inflammation and eustachian tube dysfunction. Further research is essential to clarify the mechanisms linking IgE‐mediated allergies to middle ear pathologies and to develop effective treatment strategies. Addressing these knowledge gaps is critical for improving patient outcomes and managing the rising burden of allergic diseases.
Otitis Media With Effusion (OME) and Eustachian Tube Dysfunction: The Role of Allergy and Immunity—An EAACI Position Paper
IgE‐mediated allergies play a significant role in respiratory diseases. Given the similar mucosal epithelium of the upper and lower respiratory tracts and their shared (patho)physiological immune responses, the “unified airways” concept views these tracts as a single system. Recently, this model has been extended to include the middle ear, with studies confirming that the Eustachian tube and middle ear are both anatomically and functionally part of the upper airways. However, the relationship between allergies and middle ear disorders remains controversial, with conflicting findings regarding pathogenesis and treatment. The increasing prevalence of allergies highlights the importance of further research. In Germany, the current sensitization rate to aeroallergens is 33.6%, with similar trends across Europe, where rates commonly range up to 30%. This widespread increase underscores the urgent need for a deeper understanding of the correlation between allergies and middle ear disorders across diverse European populations. Ineffective pharmacotherapy or possibly harmful medication for acute and chronic OME, such as systemic steroids, is most likely used globally in an uninformed way, due to a lack of evidence on the connection between allergic inflammation and eustachian tube dysfunction. Further research is essential to clarify the mechanisms linking IgE‐mediated allergies to middle ear pathologies and to develop effective treatment strategies. Addressing these knowledge gaps is critical for improving patient outcomes and managing the rising burden of allergic diseases.
- Open Access
- 12 March 2025
- Published by Wiley
An EAACI Task Force Scoping Review: Human Monocytes and Macrophages in Allergy – Implications for AllergoOncology
AllergoOncology explores the intersection of allergic diseases and cancer, focusing on shared immune mechanisms mediated by monocytes and macrophages. These cells exhibit high heterogeneity, plasticity, and functional diversity across tissues and disease progression, yet their roles in allergic disorders remain unclear. This scoping review systematically analyzed 138 articles, identifying 451 molecules associated with monocyte and macrophage responses in allergic diseases, including Allergic Asthma, Atopic Dermatitis, and Allergic Rhinitis. Our findings revealed a research bias toward blood-derived samples, underrepresentation of tissue-resident macrophages and limited inclusion of non-coding RNAs. Semantic similarity and pathway enrichment analyses identified shared molecular signatures across major allergic disorders, highlighting interleukin signaling and immune activation pathways. Less-studied conditions, such as Allergic Alveolitis and Food Allergy, displayed distinct molecular profiles, emphasizing the need for broader investigations. To enhance data accessibility, we developed [ALO•HA](https://rebollidorioslab.shinyapps.io/aloha/), a web application for interactive analysis. [ALO•HA](https://rebollidorioslab.shinyapps.io/aloha/) fosters reproducibility and translational potential for both researchers and clinicians. Our findings highlight the need for integrative approaches, combining omics technologies and human-based studies, to better characterize monocyte and macrophage phenotypes in allergy. This work advances the understanding of allergy-immunity interactions, bridges allergy and oncology, addresses critical gaps and opens new opportunities for therapeutic development.
- 12 March 2025
- Published by Wiley
Open AccessAn EAACI Task Force Scoping Review: Human Monocytes and Macrophages in Allergy – Implications for AllergoOncology
AllergoOncology explores the intersection of allergic diseases and cancer, focusing on shared immune mechanisms mediated by monocytes and macrophages. These cells exhibit high heterogeneity, plasticity, and functional diversity across tissues and disease progression, yet their roles in allergic disorders remain unclear. This scoping review systematically analyzed 138 articles, identifying 451 molecules associated with monocyte and macrophage responses in allergic diseases, including Allergic Asthma, Atopic Dermatitis, and Allergic Rhinitis. Our findings revealed a research bias toward blood-derived samples, underrepresentation of tissue-resident macrophages and limited inclusion of non-coding RNAs. Semantic similarity and pathway enrichment analyses identified shared molecular signatures across major allergic disorders, highlighting interleukin signaling and immune activation pathways. Less-studied conditions, such as Allergic Alveolitis and Food Allergy, displayed distinct molecular profiles, emphasizing the need for broader investigations. To enhance data accessibility, we developed [ALO•HA](https://rebollidorioslab.shinyapps.io/aloha/), a web application for interactive analysis. [ALO•HA](https://rebollidorioslab.shinyapps.io/aloha/) fosters reproducibility and translational potential for both researchers and clinicians. Our findings highlight the need for integrative approaches, combining omics technologies and human-based studies, to better characterize monocyte and macrophage phenotypes in allergy. This work advances the understanding of allergy-immunity interactions, bridges allergy and oncology, addresses critical gaps and opens new opportunities for therapeutic development.
- Open Access
Granulocytes and mast cells in AllergoOncology—Bridging allergy to cancer: An EAACI position paper
Derived from the myeloid lineage, granulocytes, including basophils, eosinophils, and neutrophils, along with mast cells, play important, often disparate, roles across the allergic disease spectrum. While these cells and their mediators are commonly associated with allergic inflammation, they also exhibit several functions either promoting or restricting tumor growth. In this Position Paper we discuss common granulocyte and mast cell features relating to immunomodulatory functions in allergy and in cancer. We highlight key mechanisms which may inform cancer treatment and propose pertinent areas for future research. We suggest areas where understanding the communication between granulocytes, mast cells, and the tumor microenvironment, will be crucial for identifying immune mechanisms that may be harnessed to counteract tumor development. For example, a comprehensive understanding of allergic and immune factors driving distinct neutrophil states and those mechanisms that link mast cells with immunotherapy resistance, might enable targeted manipulation of specific subpopulations, leading to precision immunotherapy in cancer. We recommend specific areas of investigation in AllergoOncology and knowledge exchange across disease contexts to uncover pertinent reciprocal functions in allergy and cancer and allow therapeutic manipulation of these powerful cell populations. These will help address the unmet needs in stratifying and managing patients with allergic diseases and cancer.
Open AccessGranulocytes and mast cells in AllergoOncology—Bridging allergy to cancer: An EAACI position paper
Derived from the myeloid lineage, granulocytes, including basophils, eosinophils, and neutrophils, along with mast cells, play important, often disparate, roles across the allergic disease spectrum. While these cells and their mediators are commonly associated with allergic inflammation, they also exhibit several functions either promoting or restricting tumor growth. In this Position Paper we discuss common granulocyte and mast cell features relating to immunomodulatory functions in allergy and in cancer. We highlight key mechanisms which may inform cancer treatment and propose pertinent areas for future research. We suggest areas where understanding the communication between granulocytes, mast cells, and the tumor microenvironment, will be crucial for identifying immune mechanisms that may be harnessed to counteract tumor development. For example, a comprehensive understanding of allergic and immune factors driving distinct neutrophil states and those mechanisms that link mast cells with immunotherapy resistance, might enable targeted manipulation of specific subpopulations, leading to precision immunotherapy in cancer. We recommend specific areas of investigation in AllergoOncology and knowledge exchange across disease contexts to uncover pertinent reciprocal functions in allergy and cancer and allow therapeutic manipulation of these powerful cell populations. These will help address the unmet needs in stratifying and managing patients with allergic diseases and cancer.
- Open Access
- 22 February 2024
- Published by Open Exploration Publishing
- Vol. 2, 33-48
Evaluation of ongoing mepolizumab treatment in chronic rhinosinusitis with nasal polyps
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a multifactorial inflammatory disease of the mucous membranes of the nose and paranasal sinuses. Eosinophilic inflammation is described as a comm
- 22 February 2024
- Published by Open Exploration Publishing
- Vol. 2, 33-48
Open AccessEvaluation of ongoing mepolizumab treatment in chronic rhinosinusitis with nasal polyps
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a multifactorial inflammatory disease of the mucous membranes of the nose and paranasal sinuses. Eosinophilic inflammation is described as a comm
AllergoOncology: Biomarkers and refined classification for research in the allergy and glioma nexus—A joint EAACI‐EANO position paper
Epidemiological studies have explored the relationship between allergic diseases and cancer risk or prognosis in AllergoOncology. Some studies suggest an inverse association, but uncertainties remain, including in IgE‐mediated diseases and glioma. Allergic disease stems from a Th2‐biased immune response to allergens in predisposed atopic individuals. Allergic disorders vary in phenotype, genotype and endotype, affecting their pathophysiology. Beyond clinical manifestation and commonly used clinical markers, there is ongoing research to identify novel biomarkers for allergy diagnosis, monitoring, severity assessment and treatment. Gliomas, the most common and diverse brain tumours, have in parallel undergone changes in classification over time, with specific molecular biomarkers defining glioma subtypes. Gliomas exhibit a complex tumour‐immune interphase and distinct immune microenvironment features. Immunotherapy and targeted therapy hold promise for primary brain tumour treatment, but require more specific and effective approaches. Animal studies indicate allergic airway inflammation may delay glioma progression. This collaborative European Academy of Allergy and Clinical Immunology (EAACI) and European Association of Neuro‐Oncology (EANO) Position Paper summarizes recent advances and emerging biomarkers for refined allergy and adult‐type diffuse glioma classification to inform future epidemiological and clinical studies. Future research is needed to enhance our understanding of immune–glioma interactions to ultimately improve patient prognosis and survival.
AllergoOncology: Biomarkers and refined classification for research in the allergy and glioma nexus—A joint EAACI‐EANO position paper
Epidemiological studies have explored the relationship between allergic diseases and cancer risk or prognosis in AllergoOncology. Some studies suggest an inverse association, but uncertainties remain, including in IgE‐mediated diseases and glioma. Allergic disease stems from a Th2‐biased immune response to allergens in predisposed atopic individuals. Allergic disorders vary in phenotype, genotype and endotype, affecting their pathophysiology. Beyond clinical manifestation and commonly used clinical markers, there is ongoing research to identify novel biomarkers for allergy diagnosis, monitoring, severity assessment and treatment. Gliomas, the most common and diverse brain tumours, have in parallel undergone changes in classification over time, with specific molecular biomarkers defining glioma subtypes. Gliomas exhibit a complex tumour‐immune interphase and distinct immune microenvironment features. Immunotherapy and targeted therapy hold promise for primary brain tumour treatment, but require more specific and effective approaches. Animal studies indicate allergic airway inflammation may delay glioma progression. This collaborative European Academy of Allergy and Clinical Immunology (EAACI) and European Association of Neuro‐Oncology (EANO) Position Paper summarizes recent advances and emerging biomarkers for refined allergy and adult‐type diffuse glioma classification to inform future epidemiological and clinical studies. Future research is needed to enhance our understanding of immune–glioma interactions to ultimately improve patient prognosis and survival.
- Open Access
- 9 November 2023
- Published by Wiley
AllergoOncology: Biomarkers and Refined Classification for Research in the Allergy and Glioma Nexus - a Joint EAACI-EANO Position Paper
Epidemiological studies have explored the relationship between allergic diseases and cancer risk or prognosis in AllergoOncology. Some studies suggest an inverse association, but uncertainties remain, including in IgE-mediated diseases and glioma. Allergic disease stems from a Th2-biased immune response to allergens in predisposed atopic individuals. Allergic disorders vary in phenotype, genotype, and endotype, affecting their pathophysiology. Beyond clinical manifestation and commonly used clinical markers, there is ongoing research to identify novel biomarkers for allergy diagnosis, monitoring, severity assessment, and treatment. Gliomas, the most common and diverse brain tumours, have in parallel undergone changes in classification over time, with specific molecular biomarkers defining glioma subtypes. Gliomas exhibit a complex tumour-immune interphase and distinct immune microenvironment features. Immunotherapy and targeted therapy hold promise for primary brain tumour treatment, but require more specific and effective approaches. Animal studies indicate allergic airway inflammation may delay glioma progression. This collaborative European Academy of Allergy and Clinical Immunology (EAACI) and European Association of Neuro-Oncology (EANO) Position Paper summarizes recent advances and emerging biomarkers for refined allergy and adult-type diffuse glioma classification to inform future epidemiological and clinical studies. Future research is needed to enhance our understanding of immune-glioma interactions to ultimately improve patient prognosis and survival.
- 9 November 2023
- Published by Wiley
Open AccessAllergoOncology: Biomarkers and Refined Classification for Research in the Allergy and Glioma Nexus - a Joint EAACI-EANO Position Paper
Epidemiological studies have explored the relationship between allergic diseases and cancer risk or prognosis in AllergoOncology. Some studies suggest an inverse association, but uncertainties remain, including in IgE-mediated diseases and glioma. Allergic disease stems from a Th2-biased immune response to allergens in predisposed atopic individuals. Allergic disorders vary in phenotype, genotype, and endotype, affecting their pathophysiology. Beyond clinical manifestation and commonly used clinical markers, there is ongoing research to identify novel biomarkers for allergy diagnosis, monitoring, severity assessment, and treatment. Gliomas, the most common and diverse brain tumours, have in parallel undergone changes in classification over time, with specific molecular biomarkers defining glioma subtypes. Gliomas exhibit a complex tumour-immune interphase and distinct immune microenvironment features. Immunotherapy and targeted therapy hold promise for primary brain tumour treatment, but require more specific and effective approaches. Animal studies indicate allergic airway inflammation may delay glioma progression. This collaborative European Academy of Allergy and Clinical Immunology (EAACI) and European Association of Neuro-Oncology (EANO) Position Paper summarizes recent advances and emerging biomarkers for refined allergy and adult-type diffuse glioma classification to inform future epidemiological and clinical studies. Future research is needed to enhance our understanding of immune-glioma interactions to ultimately improve patient prognosis and survival.
- Open Access
AllergoOncology: Danger signals in allergology and oncology: A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper
The immune system interacts with many nominal ‘danger’ signals, endogenous danger‐associated (DAMP), exogenous pathogen (PAMP) and allergen (AAMP)‐associated molecular patterns. The immune context under which these are received can promote or prevent immune activating or inflammatory mechanisms and may orchestrate diverse immune responses in allergy and cancer. Each can act either by favouring a respective pathology or by supporting the immune response to confer protective effects, depending on acuity or chronicity. In this Position Paper under the collective term danger signals or DAMPs, PAMPs and AAMPs, we consider their diverse roles in allergy and cancer and the connection between these in AllergoOncology. We focus on their interactions with different immune cells of the innate and adaptive immune system and how these promote immune responses with juxtaposing clinical outcomes in allergy and cancer. While danger signals present potential targets to overcome inflammatory responses in allergy, these may be reconsidered in relation to a history of allergy, chronic inflammation and autoimmunity linked to the risk of developing cancer, and with regard to clinical responses to anti‐cancer immune and targeted therapies. Cross‐disciplinary insights in AllergoOncology derived from dissecting clinical phenotypes of common danger signal pathways may improve allergy and cancer clinical outcomes.
Open AccessAllergoOncology: Danger signals in allergology and oncology: A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper
The immune system interacts with many nominal ‘danger’ signals, endogenous danger‐associated (DAMP), exogenous pathogen (PAMP) and allergen (AAMP)‐associated molecular patterns. The immune context under which these are received can promote or prevent immune activating or inflammatory mechanisms and may orchestrate diverse immune responses in allergy and cancer. Each can act either by favouring a respective pathology or by supporting the immune response to confer protective effects, depending on acuity or chronicity. In this Position Paper under the collective term danger signals or DAMPs, PAMPs and AAMPs, we consider their diverse roles in allergy and cancer and the connection between these in AllergoOncology. We focus on their interactions with different immune cells of the innate and adaptive immune system and how these promote immune responses with juxtaposing clinical outcomes in allergy and cancer. While danger signals present potential targets to overcome inflammatory responses in allergy, these may be reconsidered in relation to a history of allergy, chronic inflammation and autoimmunity linked to the risk of developing cancer, and with regard to clinical responses to anti‐cancer immune and targeted therapies. Cross‐disciplinary insights in AllergoOncology derived from dissecting clinical phenotypes of common danger signal pathways may improve allergy and cancer clinical outcomes.